semaglutide loss of exclusivity Novo Nordisk's in India ending on a court Semaglutide's 2026 Patent Expiry: Revolutionizing

The following are some insights from clinical trials and personal anecdotes to highlight Wegovys success as a weight loss drug

During the first couple of weeks, some patients report: Better skin hydration A healthier-looking glow Calmer, more refreshed-looking skin Early improvement in overall skin texture These early changes are consistent with GHK-Cus studied role in skin support and repair

It is not FDA approved: grey market native and uniquely irreverent to FDA rulings

That makes it difficult to estimate what the implant's sales could be in a GLP-1 market that some analysts expect could exceed $100 billion by the early 2030s

Seeks to support antioxidant activity

(This blog is not where Im going to discuss the nuance and potential harm of prescribing GLP-1s to teens